Health Care [ 5/12 ] | Pharmaceuticals [ 13/73 ]
NASDAQ | Common Stock
Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States.
The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options.
It is also developing sulopenem, a novel anti-infective compound with oral and intravenous formulations to treat uncomplicated urinatry tract infections, complicated urinary tract infections, and complicated intra-abdominal infections, as well as community-acquired bacterial pneumonia, acute bacterial prostatitis, gonococcal urethritis, and pelvic inflammatory diseases.
Iterum Therapeutics plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 5, 25 | -0.13 Increased by +56.67% | -0.11 Decreased by -18.18% |
| May 13, 25 | -0.10 Increased by +78.26% | -0.15 Increased by +33.33% |
| Feb 7, 25 | -0.12 Increased by +87.23% | -0.22 Increased by +45.45% |
| Nov 14, 24 | -0.24 Increased by +20.00% | -0.17 Decreased by -37.14% |
| Aug 9, 24 | -0.30 Increased by +68.42% | -0.45 Increased by +33.33% |
| May 13, 24 | -0.46 Increased by +20.69% | -0.72 Increased by +36.11% |
| Mar 28, 24 | -0.94 Decreased by -80.77% | -0.93 Decreased by -1.08% |
| Nov 14, 23 | -0.30 Increased by +69.07% | -0.91 Increased by +67.03% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 0.00 Decreased by N/A% | -6.51 M Decreased by -30.26% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -4.89 M Increased by +31.12% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 0.00 Decreased by -100.00% | -6.58 M Increased by +46.76% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -6.09 M Decreased by -57.18% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -5.00 M Increased by +59.18% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -7.10 M Increased by +28.19% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 2.62 M Increased by +N/A% | -12.36 M Decreased by -142.87% | Decreased by -471.83% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -3.88 M Increased by +86.68% | Decreased by N/A% Decreased by N/A% |